Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitric oxide - Sanotize Research and Development

Next Previous
X
Search
Drug Profile

Nitric oxide - Sanotize Research and Development

Alternative Names: Enovid; FabiSpray; Nitric Oxide Nasal Spray; Nitric oxide releasing solution; NORS 0791; NORS 1002; NORS 2791; NORS 4002; NORS 6491; NORS™

Latest Information Update: 28 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nitric Solutions
  • Developer Glenmark Pharmaceuticals Ltd; Nitric Solutions; SaNOtize Research and Development
  • Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Immunomodulators; Nitric oxide donors; Reactive oxygen species modulators; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed COVID 2019 infections
  • Phase II Rhinosinusitis; Sinusitis; Tinea pedis
  • No development reported Acne; Common cold; Diabetic foot ulcer; Onychomycosis; Warts

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Diabetic-foot-ulcer in Canada (Topical)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Warts in Canada (Topical)
  • 13 Feb 2024 Phase-II clinical trials in Rhinosinusitis in Canada (Intranasal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top